eligibility_summary
Eligible: ≤40 yrs with recurrent/progressive, incurable sarcoma, NKG2DL+ tumor (≥2+ in >50% by MICA/ULBP2) via biopsy or archive, measurable/evaluable disease, (Arm B) intralesional access, life expectancy ≥10 wks, PS ≥50, recovered from therapy, adequate marrow, hepatic <2×ULN, renal ≤1.5×ULN, consent, contraception. Exclude: other trials, active infection/major illness (LVEF<45%, HIV, CMV/EBV/HBV/HCV), organ dysfunction, chronic steroids, CTCAE ≥4, pregnant/lactating, epilepsy, PI concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I dose-escalation trial in children/adolescents/young adults with advanced sarcoma testing donor-derived NKG2D-CAR memory T cells. Intervention type: genetically engineered, allogeneic memory T-cell adoptive immunotherapy. Arms: systemic IV infusion (Arm A) or IV plus intratumoral injection into accessible lesions (Arm B). Mechanism: T cells are transduced to express a chimeric receptor using NKG2D to bind stress-induced NKG2D ligands (e.g., MICA/MICB/ULBPs) on tumor cells, activating T-cell cytotoxicity and bypassing tumor immune evasion. Patients receive lymphodepleting chemotherapy (± low-dose radiotherapy) before infusion. Targets: sarcoma cells expressing NKG2D ligands, the NKG2D immune-surveillance pathway.